News
CVAC
3.090
+11.55%
0.320
Weekly Report: what happened at CVAC last week (0422-0426)?
Weekly Report · 4d ago
COVID-19 Patent Dispute Sorted: Acuitas Therapeutics and CureVac Reach Settlement In Patent Battle
Acuitas Therapeutics and Germany-based CureVac NV have settled a lawsuit over credit for inventions tied to COVID-19 vaccines. Acuitas accused CureVAC of failing to credit it on patents related to the technology used in the vaccines. The company has previously secured a separate license for the technology employed in the vaccine.
Benzinga · 6d ago
Curevac’s Market Forecast Risks: Miscalculations and Trial Participant Challenges Threaten Profitability
TipRanks · 04/26 06:01
Acuitas, CureVac settle lawsuit over COVID-19 vaccine patent rights
Acuitas, CureVac settle lawsuit over COVID-19 vaccine patent rights. Biotech company Acuitas Therapeutics and Germany-based Curevac 5CV.DE claim credit for inventions related to the vaccine. Acuitsas sued Cure Vac last year, claiming its scientists should have been co-inventors of patents.
Reuters · 04/25 22:24
Curevac Price Target Cut to $4.00/Share From $12.00 by Leerink Partners
Dow Jones · 04/25 13:23
Curevac Cut to Market Perform From Outperform by Leerink Partners
Dow Jones · 04/25 13:23
Leerink Partners Downgrades CureVac to Market Perform, Lowers Price Target to $4
Benzinga · 04/25 13:12
Analysts Offer Insights on Healthcare Companies: CureVac (CVAC) and BioMarin Pharmaceutical (BMRN)
TipRanks · 04/25 11:51
Curevac B.V.: Report of foreign issuer
Press release · 04/25 00:51
CureVac N.V. Reports Strong 2023 Finances and Strategic Advances
TipRanks · 04/24 21:30
CureVac Launches Study for H5N1 Influenza Vaccine
TipRanks · 04/24 21:29
CureVac Names New Chief Business Officer
TipRanks · 04/24 21:28
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Boston Scientific (BSX) and CureVac (CVAC)
TipRanks · 04/24 20:30
CureVac BV reports Q4 results
CureVac BV reports Q4 results. Revenue of €22.6M (+93.2% Y/Y). Q4 pre-tax loss was €86.5 million and €260.0 million for the three and twelve months ended December 31, 2023.
Seeking Alpha · 04/24 11:30
CureVac Has Started The Phase 1 Part Of A Combined Phase 1/2 Study Of An Investigational Influenza A (H5N1) Pre-Pandemic Vaccine Candidate Developed In Collaboration With GSK, H5N1 Is An Avian Influenza Virus
Benzinga · 04/24 11:20
CureVac BV FQ4 2023 Earnings Preview
CureVac BV is scheduled to announce its FQ4 earnings results on Wednesday, April 24th. The company is expected to report earnings of -$0.15 per share. The consensus revenue estimate for the quarter is $31.52 million. CureVac N.V. (CVAC)
Seeking Alpha · 04/23 18:08
Notable earnings before Wednesday's open
Major earnings expected before the bell on Wednesday include: The Boeing, Biogen, General Dynamics, AT&T and Thermo Fisher Scientific. Other notable earnings slated for release before Wednesday's open include: Boeing, GE, TMO and others. The Boeing is expected to report its first quarter earnings after the close of trading.
Seeking Alpha · 04/23 14:25
Weekly Report: what happened at CVAC last week (0415-0419)?
Weekly Report · 04/22 10:40
CureVac (CVAC) Gets a Buy from Leerink Partners
TipRanks · 04/18 04:29
CVAC, SBNY and CRMD are among after hour movers
Seeking Alpha · 04/17 21:01
More
Webull provides a variety of real-time CVAC stock news. You can receive the latest news about Curevac B.V. through multiple platforms. This information may help you make smarter investment decisions.
About CVAC
CureVac AG is a clinical-stage biopharmaceutical company, The Company strives to create transformative medicines to protect and improve people’s lives. Fueled by proprietary RNA technology platform combined with two decades of science and manufacturing, The Company is dedicated to creating novel treatments that enable the body to make its own prophylactic and therapeutic drugs.